Short Interest in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Expands By 236.2%

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the target of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 470,700 shares, a growth of 236.2% from the August 15th total of 140,000 shares. Approximately 3.3% of the company’s shares are sold short. Based on an average trading volume of 379,400 shares, the short-interest ratio is currently 1.2 days.

NeuroSense Therapeutics Price Performance

NRSN stock traded up $0.07 on Thursday, hitting $1.29. 316,094 shares of the company were exchanged, compared to its average volume of 284,318. The stock has a market capitalization of $17.63 million, a price-to-earnings ratio of -1.52 and a beta of 1.52. NeuroSense Therapeutics has a twelve month low of $0.40 and a twelve month high of $2.33. The business’s fifty day moving average is $0.85 and its two-hundred day moving average is $1.20.

NeuroSense Therapeutics (NASDAQ:NRSN) last released its quarterly earnings data on Monday, June 24th. The company reported ($0.35) EPS for the quarter.

Hedge Funds Weigh In On NeuroSense Therapeutics

An institutional investor recently bought a new position in NeuroSense Therapeutics stock. XTX Topco Ltd purchased a new stake in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 32,650 shares of the company’s stock, valued at approximately $37,000. XTX Topco Ltd owned 0.24% of NeuroSense Therapeutics as of its most recent filing with the Securities & Exchange Commission. 1.04% of the stock is currently owned by institutional investors and hedge funds.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.